Regulatory Updates Health Sciences Authority Singapore

Similar documents
International Trend on Medical Device Regulatory Convergence

Take a Course of Action.

FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV

Mediwales Finance and Funding Event:

Raad voor Accreditatie (Dutch Accreditation Council RvA) Specific Accreditation Protocol for Certification according to ISO/IEC 13485

MEDICAL DEVICE GUIDANCE

The Health Professionals Prescribing Pathway

IAF Mandatory Document for the Application of ISO/IEC in Medical Device Quality Management Systems (ISO 13485)

SUMMARY REPORT OF THE 17 th ACCSQ MDPWG MEETING

Rules and Procedures for IMI Calls for proposals. IMI Webinar 17 July 2017

A Career in Big Pharma. Beatrice Tilt, GSK

FDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, Elizabeth Hillebrenner, MSE OIR/CDRH/FDA

Role of the Nursing Home Medical Director. Vicky Pilkington, MD, CMD

NIHR call for Global Health Research. Making an application

THE HEALTH SECTOR from EIB lending perspective. Felicitas Riedl

SCIENCE COMMITTEE PROGRAMME FOUNDATION AWARDS OUTLINE APPLICATION GUIDELINES

IVD Regulatory Update February 2015

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review

We advance science and develop innovative technology to further economic growth and improve lives.

CORPORATE PLAN

New EU legislation on Medical Devices. Erik Hansson Deputy Head of Unit European Commission DG Health and Consumers 1

Introduction of AHWP. IMDRF Stakeholder Meeting 25 March 2015

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

MEDICINES CONTROL COUNCIL

Academic Medical Centres

European IVD Regulations and Risk Based Classification. An Overview for Global Quality Professionals

2008/SOM3/SCCP/002attB Agenda Item: 3(i)

Defining the Boundaries between NHS and Private Healthcare. MECCG Policy Reference: MECCG142

Guidance for applicants requesting scientific advice

Guidance for the Applicants: Gilead Sciences Nordic Fellowship Programme 2017

3. The requirements for taking part in the ES are as follows:

National Biopharma Mission for Accelerating Early Development of Biopharmaceuticals Innovate in India (i3)

Research Design Service support for NIHR i4i applications.

Guidance on the Statement of Purpose for designated centres for Older People

IVDD revision changes to the European regulation of in-vitro diagnostic (IVD) Medical Devices. Med-Info. TÜV SÜD Product Service GmbH

Ferring Investigator-Initiated Trials (IIT) Submission Guidelines

Economic and Social Council

Pre-Submissions and Meetings with FDA Staff

Supervising pharmacist independent

LUX Photonics Consortium Industry-IHL Collaboration Seed Grant LUX Photonics Consortium Industry-IHL Collaboration Seed Grant Guidelines

Support Services Group

Research & Development Tax Measures

MSc REGULATORY AFFAIRS MEDICINES / MEDICAL DEVICES PROSPECTUS

Latin America: An Evolving Regulatory Environment September 15, Mapi 2015, All Rights Reserved

RACMA GUIDE TO PRACTICAL CREDENTIALING AND SCOPE OF CLINICAL PRACTICE PROCESSES

TIER 1 (GRADUATE ENTREPRENUR) SCHEME STUDENT GUIDE

Eligibility Criteria for NIHR Clinical Research Network Support

Massachusetts Next Generation Initiative (MassNextGen) Solicitation Fiscal Year 2018

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

Guidance for Industry and Food and Drug Administration Staff

Gilead UK & Ireland Corporate Contributions Grant FAQs

PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS

Kaiser Permanente Research A Very Brief Introduction

TECHNOLOGY DEVELOPMENT PROGRAM

The Tier 1 (Graduate Entrepreneur) Visa programme at Oxford Brookes University

FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY

Thank you for joining ISMPP U today! The program will begin promptly at 11:00 am EST

Hong Kong Association of the Pharmaceutical Industry. Position paper on Primary Care in Hong Kong

NIHR BIOMEDICAL RESEARCH CENTRES FREQUENTLY ASKED QUESTIONS

Programmatic (AME) Programmatic Funds for AME Domain

Before making an application, you should consider this additional guidance which updates existing guidance elsewhere in this document.

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

Guide to Continuing Professional Development

UNESCO Chair, Cultural Diversity and Social Justice Associate Researcher Scheme ARS GUIDELINES Table of Contents

10 Publications Committee charter and mission guidelines

The 3E Principle of Outsourcing

Guide to Continuing Professional Development

ADMINISTRATION OF INSULIN IN THE COMMUNITY BY ATTENDANT CARE SUPPORT WORKERS

Hospital Naming Directive

Improving outdoor PE and sport facilities. Primary Spaces Roles and Responsibilities Tender and Installation Process

Vertex Investigator-Initiated Studies Program Overview

UNIVERSITY OF YORK. POSTGRADUATE PROGRAMME REGULATIONS (for PGT programmes that will run under the new modular scheme)

Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015

Application Form Mauritius-Africa Scholarship

Outline. Modernizing Nursing: Advanced Practice Nursing: Singapore s Perspectives 23/05/2007. History. Definition of an APN

Closing Date for EOI: 4pm, Monday 19 March Introduction and purpose. 2. Eligibility

Translational Research Strategic Plan Continuing the Mission of the Sisters of the Little Company of Mary

SINGAPORE CHINA JOINT RESEARCH PROGRAMME. 12 th SINGAPORE CHINA JRP CALL FOR PROPOSALS. (For Singapore Applicants)

Supervision, Accountability & Delegation. date of issue April 2017

POSITION SPECIFICATIONS

THE BETTER ENTREPRENEURSHIP POLICY TOOL

Programme specification: MSc Advanced Practice (Health)

Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.

Retrospective Chart Review Studies

Compassionate Use Systems in the EU How to improve for early access to patients

Pharmacy Pain Management Protocol Pharmacy Policy and Protocol

The Practice Standards for Medical Imaging and Radiation Therapy. Radiologist Assistant Practice Standards

Guide to Incident Reporting for In-vitro Diagnostic Medical Devices

Independent prescribing conversion programme. De Montfort University Report of a reaccreditation event May 2017

Essential Conditions and Standards for Continuing Registration

Request for Proposal. Consulting Opportunity for Intellectual Property Public Education and Awareness (Phase II) [AANZ-0057-IP-09]

Philanthropic Grants Specialist

Outpatient Hospital Facilities

Support for SMEs New Business Activities in Japan. Small and Medium Enterprise Agency Ministry of Economy, Trade and Industry July 2013

HEA Accreditation Policy

Singapore China Joint Research Programme

Research Equipment Grants 2018 Scheme 2018 Guidelines for Applicants Open to members of Translational Cancer Research Centres

Turning Big Data Into Better Care

Position description. Background. Department. Nature of environment. Travel requirements. Key job requirements, responsibilities and duties

Key Population Engagement in Global Fund

Transcription:

Regulatory Updates Health Sciences Authority Singapore Wong Woei Jiuang Director, Medical Devices Branch, Health Sciences Authority, Singapore

Background Scope Pre-market Consultation (PMC) Scheme Medical Device Development Consultation Medical Device Pre-submission Consultation Priority Review Scheme Qualification Criteria Priority Review Scheme Routes

Background Support Innovation and Device Development Locally Committee Engage on the researchers Future and Economy developers (CFE) Recommendations Enable better understanding of regulatory requirements at early stage of device development Facilitate timely access for Medical Devices that demonstrate the potential to address unmet clinical needs To differentiate HSA as a trusted regulatory leader to help local enterprises expand overseas

HSA s Initiatives 1. Pre-Market Consultation Scheme Support innovation and device development by ensuring devices are in line with regulatory requirements 2. Priority Review Scheme Facilitate timely access for devices that address unmet clinical needs To provide support through the device development lifecycle DISCOVERY + IDEATION DEVELOP + PRE- CLINICAL CLINICAL REGULATORY SUBMISSION PRODUCT LAUNCH POST MARKET MONITORING

Support innovation and device development MEDICAL DEVICE PRE-MARKET CONSULTATION (PMC) SCHEME

1 Pre-Market Consultation 2 (PMC) Medical Scheme Device Channel for stakeholders to seek regulatory advice during medical device development phase to align with regulatory requirements. Medical Device Development Consultation Pre-submission Consultation Channel for stakeholders to seek feedback on their device dossier, prior to pre-market submission in terms of completeness and appropriateness of supporting documents. DISCOVERY + IDEATION DEVELOP + PRE- CLINICAL CLINICAL REGULATORY SUBMISSION PRODUC T LAUNCH POST MARKET MONITORING

1 Channel for stakeholders to seek regulatory advice during medical device development phase to align with regulatory requirements. Medical Device Development Consultation SCOPE: Clarification on regulatory requirements applicable to the device in development, which may include Regulatory requirements Device claims Safety / Performance studies Sterility Biocompatibility Risk management Clinical trials Regulatory strategy DISCOVERY + IDEATION DEVELOP + PRE- CLINICAL CLINICAL REGULATORY SUBMISSION PRODUC T LAUNCH POST MARKET MONITORING

1. Medical Device Development Consultation Who Medical device developers, researchers When Any time during device development What it is not What Endorsement of any validation plans, test protocols and/or results that were discussed in the consultation Does not guarantee approval or marketing clearance Not meant to be an iterative process For 1 specific device or a group of devices intended to be used together

SCOPE: Seek feedback on the device dossier, in accordance to prescribed Common Submission Dossier Template (CSDT) guidance template, which may include Risk Classification Registration Route Grouping Technical & administrative documents 2 Channel Medical Device Pre-submission Consultation for stakeholders to seek feedback on their device dossier, prior to pre-market submission in terms of completeness and appropriateness of supporting documents. DISCOVERY + IDEATION DEVELOP + PRE- CLINICAL CLINICAL REGULATORY SUBMISSION PRODUC T LAUNCH POST MARKET MONITORING

2. Medical Device Pre-Submission Consultation Who Stakeholders submitting medical devices for registration locally When Before submission of pre-market application to HSA What Devices to be registered in 1 single pre-market application What it is not Not a scientific evaluation of the device Does not guarantee regulatory approval or marketing clearance

Step 2: Document Submission

Pre-Market Consultation (PMC) Scheme Following are examples of queries which do not require PMC : General questions regarding registration procedures or documentary requirements for product registration. Clarification on the guidance documents on the website. To seek advice on the risk classification or grouping. During the review process of a product registration. To appeal a decision made during pre-market submission. These enquiries can be sent as general enquiries / using dedicated enquiry form(s) to HSA_MD_Info@hsa.gov.sg, or to contact officer in charge for clarification related to specific application.

Facilitate timely access for Medical Devices that demonstrate the potential to address unmet clinical needs MEDICAL DEVICE PRIORITY REVIEW SCHEME

Medical devices* to be registered via FULL Evaluation Route Route 2 Qualification Criteria 1 2 Falls under 1 of the 5 healthcare focus area Cancer Diabetes Ophthalmologic diseases Cardiovascular diseases Infectious diseases Designed & validated to meet unmet clinical needs Intended for a medical purpose with no existing alternative treatment or means of diagnosis OR Represents a breakthrough technology that provides a clinically meaningful advantage over existing legally marketed technology Route 1 * Class A and devices incorporating registrable medicinal/ therapeutic products are not eligible for the Priority Review Scheme.

Turn-Around-Time TAT (in working days) (TAT) Evaluation & Fees ($) Risk Class Class B (FULL) Class C (FULL) Class D (FULL) 25% reduction by mid 2018 Route 1 & 2 Route 1 Route 2 35% reduction by end 2019 15% increase over current fee 50% increase over current fee 120 105 4,100 5,300 165 145 6,600 8,600 235 205 13,200 17,100

Upcoming Documents Update to the Guidance on Preparation of the ASEAN CSDT* for Medical Devices and In Vitro Diagnostics (IVDs) Registration and listing of IVD analysers and instruments * Common Submission Dossier Template 16

Thank you!